Study to Measure the Impact of Antibiotics on Bacterial Flora in Adults With Acute Sinusitis

Overview

The purpose of this study is to measure the speed of microbial eradication due to azithromycin or telithromycin in acute maxillary sinusitis (AMS).

Full Title of Study: “Influence of Oral Telithromycin vs. Azithromycin on the Endogenous Microflora in Adults With Acute Sinusitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)

Detailed Description

The objectives of this study are: – To assess the impact of therapy with telithromycin vs. azithromycin on the oral microflora in patients with acute maxillary sinusitis at day 42 and to compare the duration of colonization with resistant oropharyngeal flora in patients treated with azithromycin vs. telithromycin. – To also compare the two treatment groups for rate of reinfection within 6 weeks and the susceptibility pattern of the organisms appearing during the reinfection and differences in development of resistance and the associated changes in symptom responses.

Interventions

  • Drug: Azithromycin
    • 250 mg tablets; 2 tablets once daily (500 mg) for 3 days
  • Drug: Telithromycin
    • 400 mg tablets; 2 tablets once daily (800 mg) for 5 days

Arms, Groups and Cohorts

  • Active Comparator: 1
    • Subjects assigned Azithromycin
  • Active Comparator: 2
    • Subjects assigned Telithromycin

Clinical Trial Outcome Measures

Primary Measures

  • Bacterial resistance or selection
    • Time Frame: 42 days

Secondary Measures

  • Bacteriologic outcome
    • Time Frame: 42 days

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients, either males or non-pregnant females, aged 18 to 75 years of age with clinical findings of acute maxillary sinusitis (AMS), who are amenable to serial sampling of the nasopharynx and oropharynx. – Patients are required to have specimens of nasal and nasopharyngeal drainage collected for microbiological documentation within 24 hours prior to enrollment. All patients must produce sinus fluid drainage. – All patients will produce nasal or nasopharyngeal discharge sufficient for baseline culture. – Female patients of child bearing potential must agree to use an accepted method of contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide and barrier methods, or intrauterine device [IUD]). The patient must agree to continue with the same method throughout the study. Exclusion Criteria:

  • Patients with a history of recurrent sinusitis defined as more than three episodes of sinusitis which required antibiotic therapy in the preceding 12 months – Patients with a history of chronic sinusitis defined as symptoms lasting greater than 28 days – Patients with nosocomial acquired sinusitis (e.g., hospitalization or non-ambulatory institutional confinement including nursing homes within 2 weeks) – Patients with a need for immediate surgery for maxillary sinusitis or previous sinus surgery within the past 6 months or sinus lavage within the past 7 days – Patients who are long-term (> 4 weeks) users of nasal decongestants (e.g. oxymetazoline 0.05%) – Patients with a known or suspected hypersensitivity to, or a known or suspected serious adverse reaction to, any macrolide antibiotic – Impaired hepatic or renal function (creatinine clearance [CCL] <20 ml/min) – Severe respiratory tract infections requiring hospitalization and parenteral antibiotic therapy. – Requirement for a concomitant antimicrobial agent other than topical, antiviral or antifungal agents. – Treatment with any macrolide, azalide, or ketolide antimicrobial within the 30 days prior to entry into the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CPL Associates
  • Collaborator
    • Sanofi
  • Overall Official(s)
    • Jerome J Schentag, Pharm.D., Principal Investigator, State University of NY at Buffalo
    • Joseph Paladino, Pharm.D., Study Director, State University of NY at Buffalo

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.